(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Jazz Pharmaceuticals PLC is a global biopharmaceutical company that identifies, develops, and commercializes innovative therapies for serious diseases, with a focus on neuroscience, oncology, and hematology. The companys product portfolio includes several FDA-approved treatments for rare and complex conditions, such as narcolepsy, idiopathic hypersomnia, and various types of cancer.

Jazz Pharmaceuticals commercialized products include Xywav, Xyrem, Epidiolex, Rylaze, Enrylaze, Zepzelca, Ziihera, Defitelio, and Vyxeos, which address significant unmet medical needs in the treatment of cataplexy, excessive daytime sleepiness, seizures, and various types of leukemia and lymphoma. The companys pipeline includes several promising candidates, such as Zanidatamab, Suvecaltamide, JZP815, JZP898, JZP441, JZP324, and JZP150, which are being developed for the treatment of gastroesophageal adenocarcinoma, Parkinsons disease tremor, and other serious conditions.

With a strong track record of innovation and collaboration, Jazz Pharmaceuticals has established partnerships with leading biotech companies, including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics. The companys commitment to developing and commercializing life-changing therapies has positioned it for long-term growth and success.

Analyzing the , we observe that JAZZs last price is $111.13, with a 20-day SMA of $107.58 and a 50-day SMA of $109.58, indicating a short-term uptrend. However, the 200-day SMA of $118.45 suggests a longer-term downtrend. The ATR of 4.01 (3.61%) indicates moderate volatility. Considering the , the companys market cap is approximately $6.67 billion, with a P/E ratio of 14.71 and a forward P/E of 12.32, indicating a relatively attractive valuation. The RoE of 11.90% suggests a decent return on equity.

Based on the analysis of and , our forecast suggests that JAZZ may experience a short-term correction due to the downtrend indicated by the 200-day SMA. However, the companys strong product pipeline, innovative research and development efforts, and strategic partnerships may drive long-term growth. We predict that JAZZ may reach $130-$140 in the next 6-12 months, driven by the potential approval and commercialization of its pipeline candidates, particularly Zanidatamab and JZP441. Conversely, a failure to advance its pipeline or a significant decline in sales of its commercialized products could lead to a decline in the stock price.